Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women

被引:21
作者
Dumond, Julie B. [1 ]
Nicol, Melanie R. [1 ]
Kendrick, Racheal N. [1 ]
Garonzik, Samira M. [2 ]
Patterson, Kristine B. [3 ]
Cohen, Myron S. [3 ]
Forrest, Alan [2 ]
Kashuba, Angela D. M. [1 ]
机构
[1] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
[2] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14260 USA
[3] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA
关键词
PERFORMANCE LIQUID-CHROMATOGRAPHY; REVERSE-TRANSCRIPTASE INHIBITORS; POPULATION PHARMACOKINETICS; ANTIRETROVIRAL THERAPY; HUMAN PLASMA; QUANTIFICATION; TYPE-1; DRUGS;
D O I
10.1007/s40262-012-0012-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objectives A previously published study of antiretroviral pharmacokinetics in the female genital tract of HIV-infected women demonstrated differing degrees of female genital tract penetration among antiretrovirals. These blood plasma (BP) and cervicovaginal fluid (CVF) data were co-modelled for four antiretrovirals with varying CVF exposures. Methods Six paired BP and CVF samples were collected over 24 h, and antiretroviral concentrations determined using validated liquid chromatography (LC) with UV detection or LC-mass spectrometry analytical methods. For each antiretroviral, a BP model was fit using Bayesian estimation (ADAPTS), followed by addition of a CVF model. The final model was chosen based on graphical and statistical output, and then non-linear mixed-effects modelling using S-ADAPT was performed. Population mean parameters and their variability are reported. Model-predicated area under the concentration time curve during the dosing interval (AUC(tau)) and exposure ratios of CVF AUC(tau):BP AUC(tau) were calculated for each drug. Results The base model uses first-order absorption with a lag time, a two-compartment model, and a series of transit compartments that transfer the drug from BP to CVF. Protein-unbound drug transfers into CVF for efavirenz and atazanavir; total drug transfers for lamivudine and tenofovir. CVF follows a one-compartment model for efavirenz and atazanavir, and a two-compartment model for lamivudine and tenofovir. As expected, inter-individual variability was high. Model-predicted CVF AUC(tau):BP AUC(tau) ratios are consistent with published results. Conclusions This is the first pharmacokinetic modelling of antiretroviral disposition in BP and CVF. These models will be further refined with tissue data, and used in clinical trials simulations to inform future studies of HIV preexposure prophylaxis in women.
引用
收藏
页码:809 / 822
页数:14
相关论文
共 41 条
  • [11] Prevention of HIV-1 Infection with Early Antiretroviral Therapy
    Cohen, Myron S.
    Chen, Ying Q.
    McCauley, Marybeth
    Gamble, Theresa
    Hosseinipour, Mina C.
    Kumarasamy, Nagalingeswaran
    Hakim, James G.
    Kumwenda, Johnstone
    Grinsztejn, Beatriz
    Pilotto, Jose H. S.
    Godbole, Sheela V.
    Mehendale, Sanjay
    Chariyalertsak, Suwat
    Santos, Breno R.
    Mayer, Kenneth H.
    Hoffman, Irving F.
    Eshleman, Susan H.
    Piwowar-Manning, Estelle
    Wang, Lei
    Makhema, Joseph
    Mills, Lisa A.
    de Bruyn, Guy
    Sanne, Ian
    Eron, Joseph
    Gallant, Joel
    Havlir, Diane
    Swindells, Susan
    Ribaudo, Heather
    Elharrar, Vanessa
    Burns, David
    Taha, Taha E.
    Nielsen-Saines, Karin
    Celentano, David
    Essex, Max
    Fleming, Thomas R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (06) : 493 - 505
  • [12] Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
    Colombo, Sara
    Buclin, Thierry
    Cavassini, Matthias
    Decosterd, Laurent A.
    Telenti, Amalio
    Biollaz, Jerome
    Csajka, Chantal
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (11) : 3801 - 3808
  • [13] Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA
    Cu-Uvin, S
    Caliendo, AM
    Reinert, S
    Chang, A
    Juliano-Remollino, C
    Flanigan, TP
    Mayer, KH
    Carpenter, CCJ
    [J]. AIDS, 2000, 14 (04) : 415 - 421
  • [14] D'Argenio DZ., 2009, ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software
  • [15] PROGRAM PACKAGE FOR SIMULATION AND PARAMETER-ESTIMATION IN PHARMACOKINETIC SYSTEMS
    DARGENIO, DZ
    SCHUMITZKY, A
    [J]. COMPUTER PROGRAMS IN BIOMEDICINE, 1979, 9 (02): : 115 - 134
  • [16] Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women
    Dumond, Julie B.
    Patterson, Kristine B.
    Pecha, Allison L.
    Werner, Rebecca E.
    Andrews, Emma
    Damle, Bharat
    Tressler, Randall
    Worsley, Jochen
    Kashuba, Angela D. M.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (05) : 546 - 553
  • [17] Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract
    Else, Laura J.
    Taylor, Stephen
    Back, David J.
    Khoo, Saye H.
    [J]. ANTIVIRAL THERAPY, 2011, 16 (08) : 1149 - 1167
  • [18] The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
    Eron, JJ
    Smeaton, LM
    Fiscus, SA
    Gulick, RM
    Currier, JS
    Lennox, JL
    D'Aquila, RT
    Rogers, MD
    Tung, R
    Murphy, RL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05) : 1622 - 1628
  • [19] Population Pharmacokinetics of Tenofovir in AIDS Patients
    Gagnieu, Marie-Claude
    El Barkil, Mirna
    Livrozet, Jean-Michel
    Cotte, Laurent
    Miailhes, Patrick
    Boibieux, Andre
    Guitton, Jerome
    Tod, Michel
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (11) : 1282 - 1288
  • [20] High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy
    Goujard, U
    Legrand, M
    Panhard, X
    Diquet, B
    Duval, X
    Peytavin, G
    Vincent, I
    Katlama, C
    Leport, C
    Bonnet, B
    Salmon-Céron, D
    Mentré, F
    Taburet, AM
    [J]. CLINICAL PHARMACOKINETICS, 2005, 44 (12) : 1267 - 1278